Literature DB >> 15463071

The anthelmintic action of praziquantel.

W Harnett1.   

Abstract

Although fairly expensive (around US$4.00 per single dose) praziquantel is now the most favoured drug against all forms of schistosomiasis, and against many other helminth infections. It is now marketed by four companies: E. Merck and Bayer (F.R.G.), Ames-Myers (USA), and Shin-Poon Pharmaceuticals (S. Korea). Administration of praziquantel typically causes paralysis of susceptible worms, or damage to their tegument, making them more vulnerable to host enzymes or antibody-dependent immune effector mechanisms. Other effects may also be involved. Here, Bill Harnett reviews the range of anthelmintic effects displayed by this remarkable drug.

Entities:  

Year:  1988        PMID: 15463071     DOI: 10.1016/0169-4758(88)90192-5

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  20 in total

1.  Research development of the pathogenesis pathways for neuroschistosomiasis.

Authors:  Peng Wang; Ming-Can Wu; Shi-Jie Chen; Guo-Cai Luo; Xiang-Ling Cheng; Zhan-Sheng Zhu; Guang-Rui Zhao
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

2.  Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.

Authors:  Gianfranco Arroyo; Javier A Bustos; Andres G Lescano; Isidro Gonzales; Herbert Saavedra; Silvia Rodriguez; E Javier Pretell; Pierina S Bonato; Vera L Lanchote; Osvaldo M Takayanagui; John Horton; Armando E Gonzalez; Robert H Gilman; Hector H Garcia
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

3.  Quantification of praziquantel-induced damage on the surface of adult Schistosoma mansoni worms: estimation of esterase and alkaline phosphatase activity.

Authors:  P G Fallon; C McNeice; A J Probert; M J Doenhoff
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

4.  A case of probable mixed-infection with Clonorchis sinensis and Fasciola sp.: CT and parasitological findings.

Authors:  Tae Yun Kim; Yun-Sik Lee; Ji Hye Yun; Jeong Ju Kim; Won Hyung Choi; In Hwan Oh; Hyun Ouk Song; Jong Phil Chu
Journal:  Korean J Parasitol       Date:  2010-06-17       Impact factor: 1.341

5.  Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum.

Authors:  Wei Wang; Tian-Yu Li; Yuan Ji; Guo-Li Qu; Yi-Li Qian; Hong-Jun Li; Jian-Rong Dai; You-Sheng Liang
Journal:  Parasitol Res       Date:  2013-12-11       Impact factor: 2.289

6.  Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; Mirko Zimic; Diego Escalante; Herbert Saavedra; Martin Gavidia; Lourdes Rodriguez; Enrique Najar; Hugo Umeres; E Javier Pretell
Journal:  Lancet Infect Dis       Date:  2014-07-03       Impact factor: 25.071

7.  Field efficacy of praziquantel oral paste against naturally acquired equine cestodes in Ethiopia.

Authors:  A M Getachew; G Innocent; C J Proudman; A Trawford; G Feseha; S W J Reid; B Faith; S Love
Journal:  Parasitol Res       Date:  2012-09-22       Impact factor: 2.289

8.  Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum?

Authors:  Wei Wang; Hong-Jun Li; Guo-Li Qu; Yun-Tian Xing; Zhen-Kun Yang; Jian-Rong Dai; You-Sheng Liang
Journal:  Parasitol Res       Date:  2013-10-22       Impact factor: 2.289

9.  Anthelmintic effects of Oroxylum indicum stem bark extract on juvenile and adult stages of Hymenolepis diminuta (Cestoda), an in vitro and in vivo study.

Authors:  Khirod Deori; Arun K Yadav
Journal:  Parasitol Res       Date:  2015-12-10       Impact factor: 2.289

10.  Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E.

Authors:  Colin M Fitzsimmons; Sarah Joseph; Frances M Jones; Claus M Reimert; Karl F Hoffmann; Francis Kazibwe; Gachuhi Kimani; Joseph K Mwatha; John H Ouma; Edridah M Tukahebwa; Henry C Kariuki; Birgitte J Vennervald; Narcis B Kabatereine; David W Dunne
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.